<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="DKK" hierarchy="2" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-3-1-270615-32457</iati-identifier>
  <reporting-org ref="XM-DAC-3-1" type="10" xml:lang="EN">
   <narrative xml:lang="EN">Ministry of Foreign Affairs, Denmark</narrative>
  </reporting-org>
  <title xml:lang="EN">
   <narrative xml:lang="EN">Contribution IPM 2017-2020</narrative>
  </title>
  <description type="2" xml:lang="EN">
   <narrative xml:lang="EN">Contribution IPM 2017-2020</narrative>
  </description>
  <participating-org crs-channel-code="30006" role="2" type="30" xml:lang="EN">
   <narrative xml:lang="EN">International Partnership for Microbicides</narrative>
  </participating-org>
  <participating-org ref="XM-DAC-3-1" role="1" type="10" xml:lang="EN">
   <narrative xml:lang="EN">Ministry of Foreign Affairs, Denmark</narrative>
  </participating-org>
  <other-identifier ref="Ministry of Foreign Affairs, Denmark" type="A1">
   <owner-org>
    <narrative xml:lang="EN">2017-48190</narrative>
   </owner-org>
  </other-identifier>
  <other-identifier ref="Ministry of Foreign Affairs, Denmark" type="A2">
   <owner-org>
    <narrative xml:lang="EN">2017001305</narrative>
   </owner-org>
  </other-identifier>
  <other-identifier ref="Ministry of Foreign Affairs, Denmark" type="B1">
   <owner-org>
    <narrative xml:lang="EN">DK-1</narrative>
   </owner-org>
  </other-identifier>
  <other-identifier ref="Ministry of Foreign Affairs, Denmark" type="A3">
   <owner-org>
    <narrative xml:lang="EN">DK-1-270615-32457</narrative>
   </owner-org>
  </other-identifier>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2017-01-01" type="1"></activity-date>
  <activity-date iso-date="2017-12-20" type="2"></activity-date>
  <activity-date iso-date="2020-12-23" type="4"></activity-date>
  <activity-date iso-date="2020-12-31" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">NA</narrative>
   </organisation>
   <person-name>
    <narrative xml:lang="EN">NA</narrative>
   </person-name>
   <email>NA</email>
   <mailing-address>
    <narrative xml:lang="EN">NA</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1"></recipient-region>
  <sector code="130" percentage="100" vocabulary="2" xml:lang="EN">
   <narrative xml:lang="EN">Population Policies/Programmes &amp; Reproductive Health</narrative>
  </sector>
  <sector code="13040" percentage="100" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <country-budget-items vocabulary="4">
   <budget-item code="841" percentage="100" vocabulary="4">
    <description>
     <narrative xml:lang="EN">FL &#xA7;06.36.03.11 SRSR activities with international civil society organisations</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <policy-marker code="5" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="1" significance="1" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1" xml:lang="EN">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1" xml:lang="EN"></policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1" xml:lang="EN"></policy-marker>
  <policy-marker code="12" significance="0" vocabulary="1" xml:lang="EN"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="B01" vocabulary="1"></default-aid-type>
  <budget type="1">
   <period-start iso-date="2017-10-01"></period-start>
   <period-end iso-date="2017-12-31"></period-end>
   <value currency="DKK" value-date="2017-10-01">5000000</value>
  </budget>
  <budget type="1">
   <period-start iso-date="2018-10-01"></period-start>
   <period-end iso-date="2018-12-31"></period-end>
   <value currency="DKK" value-date="2018-10-01">5000000</value>
  </budget>
  <budget type="1">
   <period-start iso-date="2019-10-01"></period-start>
   <period-end iso-date="2019-12-31"></period-end>
   <value currency="DKK" value-date="2019-10-01">5000000</value>
  </budget>
  <budget type="1">
   <period-start iso-date="2020-10-01"></period-start>
   <period-end iso-date="2020-12-31"></period-end>
   <value currency="DKK" value-date="2020-10-01">5000000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-12-20"></transaction-date>
   <value currency="DKK" value-date="2017-12-20">20000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-12-20"></transaction-date>
   <value currency="DKK" value-date="2017-12-20">5000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-11-15"></transaction-date>
   <value currency="DKK" value-date="2018-11-15">5000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-11"></transaction-date>
   <value currency="DKK" value-date="2019-12-11">5000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-14"></transaction-date>
   <value currency="DKK" value-date="2020-12-14">5000000</value>
   <flow-type code="10"></flow-type>
   <finance-type code="110"></finance-type>
   <aid-type code="B01" vocabulary="1"></aid-type>
   <tied-status code="5"></tied-status>
  </transaction>
  <related-activity ref="XM-DAC-3-1-270615" type="1"></related-activity>
  <result type="1">
   <title>
    <narrative xml:lang="EN">2019: Continued trial of vaginal ring</narrative>
   </title>
   <reference code="273699" vocabulary="99"></reference>
   <indicator aggregation-status="0" ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">Continuation of the Monthly Dapivirine Ring EMA Article 58 Review Process (seeking a scientific opinion) and announcement of Results from DREAM and HOPE &#x2013; The Dapivirine Ring OLE (Phase IIIB) Trials.</narrative>
    </title>
    <period>
     <period-start iso-date="2019-01-01"></period-start>
     <period-end iso-date="2019-12-31"></period-end>
     <target value="MPT microbicide contraceptive vaginal ring"></target>
     <actual value="IPM completed the submission of responses to EMA Day 180 list of outstanding issues (LoOI) and the EMA&#x2019;s 2nd LoOI; the South African Health Products Regulatory Agency (SAHPRA) dossier was also updated to include the responses as planned. Further, IPM completed pre-new drug application (NDA) consolation meetings with the FDA.

IPM continued to progress the clinical development programs for both products (three-month dapivirine ring and the dapivirine-contraceptive ring).

In 2019, IPM completed the end-user segmentation studies in four target countries and initiated end-user positioning and messaging work. IPM also completed the Knowledge, Attitudes and Practices of HCPs towards the Dapivirine Vaginal Ring study and disseminated the results in Q4 2019."></actual>
    </period>
   </indicator>
  </result>
  <result type="2">
   <title>
    <narrative xml:lang="EN">Overall: Regulatory approval of vaginal ring</narrative>
   </title>
   <reference code="273696" vocabulary="99"></reference>
   <indicator aggregation-status="0" ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">N/A</narrative>
    </title>
    <period>
     <period-start iso-date="2020-01-01"></period-start>
     <period-end iso-date="2020-12-31"></period-end>
     <target value="N/A"></target>
     <actual value="N/A"></actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">2020: Regulatory approval of vaginal ring</narrative>
   </title>
   <reference code="273700" vocabulary="99"></reference>
   <indicator aggregation-status="0" ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">EMA Issued a Positive Opinion for the monthly DVR and the World Health Organization (WHO) Prequalified the DVR.</narrative>
    </title>
    <period>
     <period-start iso-date="2020-01-01"></period-start>
     <period-end iso-date="2020-12-31"></period-end>
     <target value="Dapivirine ring"></target>
     <actual value="Now seeking regulatory approvals for its use.

IPM completed DVR manufacturing launch readiness activities and began DVR commercial manufacturing in October 2020. In parallel, IPM completed end-user social marketing and HCP information, education and communications (IEC) materials development."></actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">2017: Clinical trial of vaginal ring</narrative>
   </title>
   <reference code="273697" vocabulary="99"></reference>
   <indicator aggregation-status="0" ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">MPT microbicide contraceptive vaginal ring advanced to clinical trials</narrative>
    </title>
    <period>
     <period-start iso-date="2017-01-01"></period-start>
     <period-end iso-date="2017-12-31"></period-end>
     <target value="Vaginal ring advanced to clinical trial"></target>
     <actual value="The Phase I clinical trial of IPM&#x2019;s three-month dapivirine-contraceptive ring began in May 2017"></actual>
    </period>
   </indicator>
  </result>
  <result type="1">
   <title>
    <narrative xml:lang="EN">2018: Continued clinical trial of vaginal ring</narrative>
   </title>
   <reference code="273698" vocabulary="99"></reference>
   <indicator aggregation-status="0" ascending="1" measure="1">
    <title>
     <narrative xml:lang="EN">Completion of DREAM and HOPE &#x2013; The Dapivirine Ring OLE (Phase IIIB) Trials.</narrative>
    </title>
    <period>
     <period-start iso-date="2018-01-01"></period-start>
     <period-end iso-date="2018-12-31"></period-end>
     <target value="dapivirine vaginal ring"></target>
     <actual value="the trial will remain ongoing in 2019"></actual>
    </period>
   </indicator>
  </result>
 </iati-activity>
</iati-activities>
